| ID | 10054 |
| Vaccine Name | EpiVacCorona |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Approved |
| Manufacturer | Vector State Research Centre of Viralogy and Biotechnology |
| Year of Manufacturing | NA |
| Manufacturing Country | Russia |
| Age | NA |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | Russian Federation |
| Collaborating Organisation | NA |
| Other Countries | Russia, Cambodia |
| Trade Name | EpiVacCorona-N, Aurora-CoV |
| PMID | NA |
| Clinical Trial ID | NCT04780035 |
| Reference Link | https://www.cnbc.com/2020/10/14/russia-approves-second-covid-19-vaccine-after-preliminary-trials-.html |
| Additional Links | https://www.precisionvaccinations.com/vaccines/epivaccorona-vaccine#:~:text=EpiVacCorona%20(Aurora%2DCoV)%20is,19%20and%20promotes%20immunity%20development.
|